Morin and Esculetin supplementation modulates c-myc induced energy metabolism and attenuates neoplastic changes in rats challenged with the procarcinogen 1,2 - dimethylhydrazine

European Journal of Pharmacology

Volumn 796, Issue , 2017, Pages 20-31

  Sharma, Sharada H ^a   Thulasingam, Senthilkumar ^a   Chellappan, David Raj ^a   Chinnaswamy, Prabu ^a   Nagarajan, Sangeetha ^a  

^a SASTRA UNIVERSITY   (India)

Author keywords

Chemoprevention; Colon cancer; Esculetin; Glutaminolysis; Glycolysis; Morin

Indexed keywords

1,2 DIMETHYLHYDRAZINE; ARGYROPHILIC NUCLEOLAR ANTIGEN; BETA CATENIN; CYCLINE; ESCULETIN; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUTAMINASE; GLUTAMINE; HEXOKINASE 2; LACTATE DEHYDROGENASE A; MEMBRANE PROTEIN; MORIN; MYC PROTEIN; PHOSPHOTRANSFERASE; PROTEIN SLC1A5; PYRUVATE KINASE M2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FLAVONOID; UMBELLIFERONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BETA CATENIN ACCUMULATED CRYPT; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; EATING HABIT; ENERGY METABOLISM; GENE EXPRESSION; GLUTAMINOLYSIS; GLYCOLYSIS; MALE; MONOTHERAPY; MUCIN DEPLETED FOCI; NEOPLASTIC CHANGE; NONHUMAN; ONCOGENE C FOS; ONCOGENE C JUN; ONCOGENE C MYC; PHYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCORING SYSTEM; SIGNAL TRANSDUCTION; SURVIVAL RATE; WEIGHT GAIN; ANIMAL; CARCINOGENESIS; CHEMICALLY INDUCED; COLON; COLONIC NEOPLASMS; DRUG EFFECTS; METABOLISM; PATHOLOGY; TUMOR VOLUME; WISTAR RAT;

1,2-DIMETHYLHYDRAZINE; ANIMALS; ANTICARCINOGENIC AGENTS; BETA CATENIN; BODY WEIGHT; CARCINOGENESIS; CELL PROLIFERATION; COLON; COLONIC NEOPLASMS; ENERGY METABOLISM; FLAVONOIDS; GLYCOLYSIS; MALE; PROTO-ONCOGENE PROTEINS C-MYC; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR BURDEN; UMBELLIFERONES;

EID: 85006745462     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2016.12.019     Document Type: Article

References (51)

1. Attar, R., Tabassum, S., Fayyaz, S., Ahmad, M.S., Nogueira, D.R., Yaylim, I., Timirci-Kahraman, O., Kucukhuseyin, O., Cacina, C., Farooqi, A.A., Ismail, M., Natural products are the future of anticancer therapy: preclinical and clinical advancements of Viscum album phytometabolites. Cell Mol. Biol. 61 (2015), 62–68.
2. Birnbaum, M.J., Haspel, H.C., Rosen, O.M., Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science 235 (1987), 1495–1498.
3. Blum, C.A., Xu, M., Orner, G.A., Fong, A.T., Bailey, G.S., Stoner, G.D., Horio, D.T., Dashwood, R.H., Beta-Catenin mutation in rat colon tumors initiated by 1,2-dimethylhydrazine and 2-amino-3-methylimidazo[4,5-f]quinoline, and the effect of post-initiation treatment with chlorophyllin and indole-3-carbinol. Carcinogenesis 22 (2001), 315–320.
4. Bommer, G.T., Fearon, E.R., Role of c-Myc in Apc mutant intestinal phenotype: case closed or time for a new beginning?. Cancer Cell 11 (2007), 391–394.
5. Cerella, C., Radogna, F., Dicato, M., Diederich, M., Natural compounds as regulators of the cancer cell metabolism. Int. J. Cell Biol., 2013, 2013, 639401.
6. Cho, J.H., Shin, J.C., Cho, J.J., Choi, Y.H., Shim, J.H., Chae, J.I., Esculetin (6,7-dihydroxycoumarin): a potential cancer chemopreventive agent through suppression of Sp1 in oral squamous cancer cells. Int. J. Oncol. 46 (2015), 265–271.
7. Dang, C.V., Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res. 70 (2010), 859–862.
8. Dang, C.V., O'donnell, K.A., Juopperi, T., The great MYC escape in tumorigenesis. Cancer Cell 8 (2005), 177–178.
9. Derenzini, M., Pession, A., Trerè, D., Quantity of nucleolar silver-stained proteins is related to proliferating activity in cancer cells. Lab. Investig. 63 (1990), 137–140.
10. Eilers, M., Eisenman, R.N., Myc's broad reach. Genes Dev. 22 (2008), 2755–2766.
11. Fayyaz, S., Aydin, T., Cakir, A., Gasparri, M.L., Panici, P.B., Farooqi, A.A., Oleuropein mediated targeting of signaling network in cancer. Curr. Top. Med. Chem. 16 (2016), 2477–2483.
12. Femia, A.P., Bendinelli, B., Giannini, A., Salvadori, M., Pinzani, P., Dolara, P., et al. Mucin-depleted foci have beta-catenin gene mutations, altered expression of its protein, and are dose- and time-dependent in the colon of 1,2-dimethylhydrazine-treated rats. Int. J. Cancer 116 (2005), 9–15.
13. Femia, A.P., Dolara, P., Giannini, A., Salvadori, M., Biggeri, A., Caderni, G., Frequent mutation of Apc gene in rat colon tumors and mucin-depleted foci, preneoplastic lesions in experimental colon carcinogenesis. Cancer Res. 67 (2007), 445–449.
14. Flier, J.S., Mueckler, M.M., Usher, P., Lodish, H.F., Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 235 (1987), 1492–1495.
15. Freie, B.W., Eisenman, R.N., Ratcheting Myc. Cancer Cell 14 (2008), 425–426.
16. Gordan, J.D., Thompson, C.B., Simon, M.C., HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12 (2007), 108–113.
17. Gupta, V., Bamezai, R.N., Human pyruvate kinase M2: a multifunctional protein. Protein Sci. 19 (2010), 2031–2044.
18. Hall, P.A., Levison, D.A., Woods, A.L., Yu, C.C., Kellock, D.B., Watkins, J.A., et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J. Pathol. 162 (1990), 285–294.
19. Jabeen, S., Qureshi, M., Attar, R., Aslam, A., Kanwal, S., Khalid, S., Qureshi, J.M., Aras Perk, A., Farooqi, A.A., Ismail, M., How sesquiterpenes modulate signaling cascades in cancers. Cell Mol. Biol. 62 (2016), 110–117.
20. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J. Clin. 61 (2011), 69–90.
21. Jeon, Y.J., Jang, J.Y., Shim, J.H., Myung, P.K., Chae, J.I., Esculetin, a Coumarin derivative, exhibits anti-proliferative and pro-apoptotic activity in G361 human malignant melanoma. J. Cancer Prev. 20 (2015), 106–112.
22. Kaneko, T., Tahara, S., Takabayashi, F., Suppression of lipid hydroperoxide-induced oxidative damage to cellular DNA by esculetin. Biol. Pharm. Bull. 26 (2003), 840–844.
23. Karthik Kumar, V., Vennila, S., Nalini, N., Effect of morin on DMH-induced biochemical changes and aberrant crypt foci formation in experimental colon carcinogenesis. Environ. Toxicol. Pharm. 29 (2010), 50–57.
24. Kim, K.M., Lee, E.J., Kim, Y.H., Chang, D.K., Odze, R.D., KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype. Am. J. Surg. Pathol. 34 (2010), 667–675.
25. Lee, S.K., Chang, H.J., Kim, T.I., Kim, W.H., Park, C.K., Chang, D.K., et al. Clinicopathologic findings of colorectal traditional and sessile serrated adenomas in Korea: a multicenter study. Digestion 77 (2008), 178–183.
26. Li, Y.H., Niu, Y.B., Sun, Y., Zhang, F., Liu, C.X., Fan, L., Mei, Q.B., Role of phytochemicals in colorectal cancer prevention. World J. Gastroenterol. 21 (2015), 9262–9272.
27. Lin, C.Y., Lovén, J., Rahl, P.B., Paranal, R.M., Burge, C.B., Bradner, J.E., et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151 (2012), 56–67.
28. Lin, X., Farooqi, A.A., Ismail, M., Recent progress in fungus-derived bioactive agents for targeting of signaling machinery in cancer cells. Drug Des. Dev. Ther. 9 (2015), 1797–1804.
29. Mazurek, S., Boschek, C.B., Hugo, F., Eigenbrodt, E., Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 15 (2005), 300–308.
30. Miller, D.M., Thomas, S.D., Islam, A., Muench, D., Sedoris, K., c-Myc and cancer metabolism. Clin. Cancer Res. 18 (2012), 5546–5553.
31. Noguchi, Y., Saito, A., Miyagi, Y., Yamanaka, S., Marat, D., Doi, C., et al. Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett. 154 (2000), 175–182.
32. Park, C., Jin, C.Y., Kim, G.Y., Choi, I.W., Kwon, T.K., Choi, B.T., et al. Induction of apoptosis by esculetin in human leukemia U937 cells through activation of JNK and ERK. Toxicol. Appl. Pharmacol. 227 (2008), 219–228.
33. Pedersen, P.L., Mathupala, S., Rempel, A., Geschwind, J.F., Ko, Y.H., Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim. Biophys. Acta 1555 (2002), 14–20.
34. Perk, A.A., Shatynska-Mytsyk, I., Gerçek, Y.C., Boztaş, K., Yazgan, M., Fayyaz, S., Farooqi, A.A., Rutin mediated targeting of signaling machinery in cancer cells. Cancer Cell Int., 14, 2014, 124.
35. Pino, M.S., Chung, D.C., The chromosomal instability pathway in colon cancer. Gastroenterology 138 (2010), 2059–2072.
36. Salter, D.W., Baldwin, S.A., Lienhard, G.E., Weber, M.J., Proteins antigenically related to the human erythrocyte glucose transporter in normal and Rous sarcoma virus-transformed chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA 79 (1982), 1540–1544.
37. Sangeetha, N., Nalini, N., Silibinin modulates caudal-type homeobox transcription factor (CDX2), an intestine specific tumor suppressor to abrogate colon cancer in experimental rats. Hum. Exp. Toxicol. 34 (2015), 56–64.
38. Sangeetha, N., Aranganathan, S., Panneerselvam, J., Shanthi, P., Rama, G., Nalini, N., Oral supplementation of silibinin prevents colon carcinogenesis in a long term preclinical model. Eur. J. Pharmacol. 643 (2010), 93–100.
39. Sehitoglu, M.H., Farooqi, A.A., Qureshi, M.Z., Butt, G., Aras, A., Anthocyanins: targeting of signaling networks in cancer cells. Asian Pac. J. Cancer Prev. 15 (2014), 2379–2381.
40. Seyfried, T.N., Shelton, L.M., Cancer as a metabolic disease. Nutr. Metab., 7, 2010, 7.
41. Shinohara, Y., Yamamoto, K., Kogure, K., Ichihara, J., Terada, H., Steady state transcript levels of the type II hexokinase and type 1 glucose transporter in human tumor cell lines. Cancer Lett. 82 (1994), 27–32.
42. Stine, Z.E., Walton, Z.E., Altman, B.J., Hsieh, A.L., Dang, C.V., MYC, metabolism, and cancer. Cancer Discov. 5 (2015), 1024–1039.
43. Trerè, D., AgNOR staining and quantification. Micron 31 (2000), 127–131.
44. Wise, D.R., DeBerardinis, R.J., Mancuso, A., Sayed, N., Zhang, X.Y., Pfeiffer, H.K., et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. USA 105 (2008), 18782–18787.
45. Witaicenis, A., Seito, L.N., Di Stasi, L.C., Intestinal anti-inflammatory activity of esculetin and 4-methylesculetin in the trinitrobenzenesulphonic acid model of rat colitis. Chem. Biol. Interact. 186 (2010), 211–218.
46. Wong, N., Ojo, D., Yan, J., Tang, D., PKM2 contributes to cancer metabolism. Cancer Lett. 356 (2015), 184–191.
47. Xu, X., Li, J., Sun, X., Guo, Y., Chu, D., Wei, L., et al. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression. Oncotarget 6 (2015), 26161–26176.
48. Yachida, S., Mudali, S., Martin, S.A., Montgomery, E.A., Iacobuzio-Donahue, C.A., Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am. J. Surg. Pathol. 33 (2009), 1823–1832.
49. Yamada, Y., Yoshimi, N., Hirose, Y., Kawabata, K., Matsunaga, K., Shimizu, M., et al. Frequent beta-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res. 60 (2000), 3323–3327.
50. Yamada, Y., Yoshimi, N., Hirose, Y., Matsunaga, K., Katayama, M., Sakata, K., et al. Sequential analysis of morphological and biological properties of beta-catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res. 61 (2001), 1874–1878.
51. Zhao, Y., Butler, E.B., Tan, M., Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis., 4, 2013, e532.